Incorporating Pragmatic Elements in Study Designs to Enhance Oncology Randomized Clinical Trials
A FRIENDS OF CANCER RESEARCH WHITE PAPER The article explores the complex landscape of determining optimal drug doses in early-phase oncology trials, with a focus on achieving a delicate balance between efficacy and safety. Traditionally centered on the maximum tolerated dose (MTD), contemporary therapies require a paradigm shift towards premarket dose optimization. Guided by Project … Continued